Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle.

TitleAnalyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle.
Publication TypeJournal Article
Year of Publication2017
AuthorsBainbridge, MN, Cooney, E, Miller, M, Kennedy, AD, Wulff, JE, Donti, T, Jhangiani, SN, Gibbs, RA, Elsea, SH, Porter, BE, Graham, BH
JournalMol Genet Metab
Volume121
Issue4
Pagination314-319
Date Published2017 Aug
ISSN1096-7206
Abstract

OBJECTIVE: To interrogate the metabolic profile of five subjects from three families with rare, nonsense and missense mutations in SLC13A5 and Early Infantile Epileptic Encephalopathies (EIEE) characterized by severe, neonatal onset seizures, psychomotor retardation and global developmental delay.

METHODS: Mass spectrometry of plasma, CSF and urine was used to identify consistently dysregulated analytes in our subjects.

RESULTS: Distinctive elevations of citrate and dysregulation of citric acid cycle intermediates, supporting the hypothesis that loss of SLC13A5 function alters tricarboxylic acid cycle (TCA) metabolism and may disrupt metabolic compartmentation in the brain.

SIGNIFICANCE: Our results indicate that analysis of plasma citrate and other TCA analytes in SLC13A5 deficient patients define a diagnostic metabolic signature that can aid in diagnosing children with this disease.

DOI10.1016/j.ymgme.2017.06.009
Alternate JournalMol. Genet. Metab.
PubMed ID28673551
Grant ListR01 GM098387 / GM / NIGMS NIH HHS / United States